Zevra Therapeutics (NASDAQ:ZVRA) is gearing up to announce its quarterly earnings on Monday, 2026-03-09. Here's a quick overview of what investors should know before the release.

Analysts are estimating that Zevra Therapeutics will report an earnings per share (EPS) of $0.05.

Anticipation surrounds Zevra Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.

New investors should understand that while earnings performance is important, market reactions are often driven by guidance.

Past Earnings Performance

In the previous earnings release, the company beat EPS by $0.02, leading to a 9.73% drop in the share price the following trading session.

Here's a look at Zevra Therapeutics's past performance and the resulting price change:

Stock Performance

Shares of Zevra Therapeutics were trading at $8.79 as of March 05. Over the last 52-week period, shares are up 8.0%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.

Discovering Zevra Therapeutics: A Closer Look

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

A Deep Dive into Zevra Therapeutics's Financials

Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.

Revenue Growth: Zevra Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2025, the company achieved a revenue growth rate of approximately 605.36%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: Zevra Therapeutics's net margin excels beyond industry benchmarks, reaching -2.09%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Zevra Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -0.43%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Zevra Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -0.21%, the company may face hurdles in achieving optimal financial performance.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.47.

To track all earnings releases for Zevra Therapeutics visit their earnings calendar on our site.

This article was generated by Benzinga's automated content engine and reviewed by an editor.